Article
BRAF/MEK inhibition in NSCLC: mechanisms of resistance and how to overcome it.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico - 1 Jan 2023
Tsamis Ioannis, Gomatou Georgia, Chachali Stavroula Porfyria, Trontzas Ioannis Panagiotis, Patriarcheas Vasileios, Panagiotou Emmanouil, Kotteas Elias
Abstract excerpt
Targeted therapy for oncogenic genetic alterations has changed the treatment paradigm of advanced non-small cell lung cancer (NSCLC). Mutations in the BRAF gene are detected in approximately 4% of patients and result in hyper-activation of the MAPK pathway, leading to uncontrolled cellular proliferation. Inhibition of BRAF and its downstream effector MEK constitutes a therapeutic strategy for a subset of patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.